Brand-Name vs Compounded GLP-1 Medications: What Changed and What It Means

What compounding actually means

Compounding is a pharmacist preparing a medication for an individual patient rather than dispensing a finished product from a manufacturer. It is a legitimate, long-standing part of pharmacy practice — a liquid version for someone who cannot swallow pills, a formulation without a dye the patient reacts to, a strength that is not commercially available.

Compounded drugs are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality before they reach patients, and that is true whether the pharmacy is excellent or terrible. The oversight that exists applies to the pharmacy and its practices, not to each product it makes.

Why compounded GLP-1s became so widely available

Federal law allows compounders to prepare copies of an approved drug when that drug is on the FDA's official shortage list. Semaglutide and tirzepatide were both on that list during the demand surge, which opened the door to a large compounded market served by telehealth companies at a fraction of brand pricing.

That door was tied directly to the shortage designation. When the shortages ended, so did the legal basis for producing what the FDA calls 'essentially a copy' of the approved drug.

• •The FDA removed tirzepatide from its shortage list in late 2024, with enforcement deadlines for compounders following in early 2025.
• •The FDA declared the semaglutide shortage resolved on February 21, 2025, with its own staged deadlines for 503A pharmacies and 503B outsourcing facilities.
• •After those deadlines, mass-compounded copies of semaglutide and tirzepatide were no longer permitted.

So why is compounded GLP-1 still being sold?

Because the rule bars copies, not compounding itself. A compounder can still prepare a formulation for an individual patient when there is a documented clinical need that the approved product does not meet — a different concentration, a formulation without an excipient the patient reacts to, or a combination product.

That is the legal opening most remaining programs operate through, and it is why you now see compounded GLP-1s marketed as personalized formulations, or combined with additives such as B12, niacinamide, L-carnitine, glycine, or NAD+.

How defensible any individual program's use of that pathway is varies enormously. Some are careful clinical operations. Others are volume businesses that apply a personalization label to what is functionally still a copy. From the outside, the marketing looks similar.

What changed in 2026

The regulatory direction through 2026 has been toward closing the compounding pathway further, not reopening it.

On April 1, 2026, the FDA issued a reminder to compounders that specific conditions must be met for a compounded drug to qualify for the exemptions under sections 503A and 503B — a direct signal to programs operating in the grey area between legitimate personalization and copies by another name.

On April 30, 2026, the FDA went further and proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, on the finding that there is no clinical need for outsourcing facilities to compound them. The FDA has also issued warning letters to 503B outsourcing facilities specifically about GLP-1 compounding.

• •If that proposal is finalized, 503B outsourcing facilities would lose the bulk-substance route for these three molecules entirely.
• •503A pharmacies compounding for an individual patient with a documented clinical need remain the narrower surviving pathway, and it is under scrutiny.
• •This is a live regulatory process, not a settled state. Check the current FDA position before assuming any specific arrangement will still exist in six months.
• •Practically: if you are choosing a compounded program, ask what happens to your prescription and your price if the pharmacy can no longer supply it.

Side-by-side comparison

The dosing risk nobody advertises

Brand-name GLP-1s come in pens with fixed, pre-set doses. Many compounded products come as a vial and a syringe, with the patient drawing up a volume based on instructions.

The FDA has reported dosing errors with compounded GLP-1s, including patients drawing up many times the intended dose after confusing units, milligrams, and milliliters. Some of those errors resulted in hospitalization. This is a mechanical risk that has nothing to do with the molecule and everything to do with the delivery format.

• •If you are given a vial and syringe, have the pharmacy or prescriber walk you through the exact dose in the units marked on your syringe.
• •Never convert doses yourself between products or between concentrations.
• •Ask whether the program supplies pre-filled syringes or pens rather than vials.
• •Keep the pharmacy's phone number, not just the telehealth company's.

Questions to ask before buying a compounded GLP-1

• •Which pharmacy prepares my medication, and is it a 503A pharmacy or a 503B outsourcing facility? You are entitled to know who made your drug.
• •What is the clinical justification for a compounded formulation in my case, specifically?
• •Is the product a plain semaglutide or tirzepatide, or is it combined with other ingredients? What is the evidence for the combination?
• •What form does it arrive in — pen, pre-filled syringe, or vial?
• •What is the beyond-use date, and how should it be stored?
• •What happens if the pharmacy stops being able to supply it — do I get switched to a brand-name product, and at what price?
• •Does the program's price change as my dose escalates?

When each one makes sense

If your insurance covers a brand-name GLP-1 for your indication, that is almost always the better choice on both cost and oversight. Verify coverage before assuming otherwise, and remember that a diabetes indication is covered far more often than a weight-management one.

If you are uninsured, compare the manufacturers' direct self-pay prices against compounded pricing before concluding that compounded is the only affordable route. That gap narrowed considerably after 2025.

If you have a documented clinical reason that an approved product does not work for you, compounding exists precisely for that case — and that is a conversation with a prescriber, not a checkout decision.

Frequently Asked Questions